News - Cell Therapeutics

Filter

Current filters:

Cell Therapeutics

Popular Filters

Cell Thera’s NHL drug Pixuvri gets backing from UK’s NICE

27-02-2014

US biotech firm Cell Therapeutics has received positive news from the UK’s drugs watchdog for use of…

BiotechnologyCell TherapeuticsNorthern EuropeOncologyPixuvriPricingRegulationUK

Cell Therapeutics to reacquire rights to two anti-cancer compounds

13-01-2014

US biotech firm Cell Therapeutics says it has reached an agreement with partner Novartis to reacquire…

BiotechnologyCell TherapeuticsLicensingNovartisOncologyOpaxioPixuvri

FDA lifts partial clinical hold on Cell Therapeutics’ tosedostat

FDA lifts partial clinical hold on Cell Therapeutics’ tosedostat

02-01-2014

US biotech firm Cell Therapeutics has received notification from the US Food and Drug Administration…

BiotechnologyCell TherapeuticsNorth AmericaOncologyRegulationtosedostatUSA

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

31-12-2013

US biotech firm Cell Therapeutics’ Pixuvri (pixantrone), a treatment for an aggressive type of cancer…

BiotechnologyCell TherapeuticsEuropeOncologyPixuvriPricingRegulation

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri

04-12-2013

US biotech firm Cell Therapeutics has concluded an agreement with the Germany’s National Association…

BiotechnologyCell TherapeuticsOncologyPixuvriPricingRare diseases

Baxter buys exclusive rights to CTI’s cancer drug pacritinib

18-11-2013

USA-based companies Baxter International and Cell Therapeutics have entered into an exclusive worldwide…

Baxter InternationalCell TherapeuticsFinancialGlobalLicensingOncologypacritinibPharmaceutical

UK’s NICE reconsiders backing for lymphoma drug Pixuvri

15-10-2013

The UK's National Institute for Health and Care Excellence has launched a second consultation on draft…

Cell TherapeuticsEuropeOncologyPharmaceuticalPixuvriPricingRegulation

Non-Hodgkin lymphoma treatment Pixuvri given market access in France

19-08-2013

USA-based Cell Therapeutics (Nasdaq: CTIC) has been granted market access in France for its aggressive…

Cell TherapeuticsEuropeOncologyPharmaceuticalPixuvriRegulation

US FDA puts partial clinical hold on Cell Thera's blood cancer drug tosedostat trial

25-06-2013

US biotech firm Cell Therapeutics (Nasdaq: CTIC) revealed this week in a filing with the Securities Exchange…

BiotechnologyCell TherapeuticsNorth AmericaOncologyRegulationResearchtosedostat

Germany's G-BA issues final assessment for Cell Thera's Pixuvri

21-05-2013

USA-based Cell Therapeutics (Nasdaq: CTIC) says that Germany's Federal Joint Committee (G-BA) has issued…

BiotechnologyCell TherapeuticsEuropeOncologyPharmaceuticalPixuvriPricingRegulation

Positive NICE recommendation for Novartis' Lucentis, but not for Cell Thera's Pixuvri

11-04-2013

There was good news for Swiss drug major Novartis (NOVN: VX) this morning, when UK drugs watchdog the…

BiotechnologyCell TherapeuticsEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPixuvriPricingRegulation

Cell Therapeutics initiates launch of Pixuvri in Europe

12-09-2012

Following the European approval of the drug this spring (The Pharma Letter May 14), US biotech firm Cell…

BiotechnologyCell TherapeuticsEuropeMarkets & MarketingOncologyPixuvriRare diseases

Cell Therapeutics prepares for Pixuvri launch; posts 2nd-qtr results

01-08-2012

US biotech firm Cell Therapeutics (Nasdaq: CTIC) yesterday reported second-quarter 2012 financial results…

BiotechnologyCell TherapeuticsFinancialMarkets & MarketingOncologypacritinibPixuvriRare diseasesResearchtosedostat

Cell Therapeutics prepares for EU launch of Pixuvri

21-06-2012

USA-based biotech company Cell Therapeutics (Nasdaq and MTA: CTIC) said yesterday that it is re-aligning…

BiotechnologyCell TherapeuticsEuropeMarkets & MarketingOncologypacritinibPixuvriResearchtostedostat

Cell Therapeutics' Pixuvri cleared in EU for NHL

14-05-2012

US biotech firm Cell Therapeutics (Nasdaq and MTA: CTIC) last week received conditional marketing authorization…

BiotechnologyCell TherapeuticsEuropeOncologyPharmaceuticalPixuvriRegulation

Cell Therapeutics to acquire pacritinib, a potential myelofibrosis drug

20-04-2012

US biotech firm Cell Therapeutics (Nasdaq and MTA: CTIC) and Singapore-based S*BIO Pte have entered into…

BiotechnologyCell TherapeuticsImmunologicalsLicensingOncologypacritinibS*BIO

Cell Therapeutics updates on Pixuvri

30-01-2012

Seattle, USA-based Cell Therapeutics (Nasdaq and MTA: CTIC) says that it has voluntarily withdrawn its…

BiotechnologyCell TherapeuticsNorth AmericaOncologyPixuvriRegulation

FDA advisory to review Cell Thera’s re-submitted pixantrone NDA

03-01-2012

The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review Cell Therapeutics’…

Cell TherapeuticsNorth AmericaOncologyPharmaceuticalpixantronePixuvriRegulation

Back to top